{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of systems biology is the ability to create quantitative models of core signaling nodes. This practice focuses on the critical balance between phosphatidylinositol 3,4,5-trisphosphate (PIP3) production by PI3K and its degradation by PTEN. By applying steady-state analysis with standard Michaelis-Menten and first-order kinetics, you can build a predictive model of this essential cellular switch. This exercise  provides a tangible application, asking you to quantify how a well-known cancer mutation in $PIK3CA$ alters pathway output, a foundational skill for understanding disease mechanisms at a molecular level.",
            "id": "4358801",
            "problem": "A central control point in the phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin (PI3K–AKT–mTOR) signaling axis is the balance between the formation and removal of phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the plasma membrane. Consider a well-mixed membrane patch in which phosphoinositide 3-kinase (PI3K) converts phosphatidylinositol 4,5-bisphosphate (PIP2) to PIP3 and Phosphatase and Tensin homolog (PTEN) dephosphorylates PIP3 back to PIP2. Assume that PIP3 production by PI3K follows Michaelis–Menten kinetics with maximal rate $V_{\\max}$ and Michaelis constant $K_{m}$, that PTEN-mediated dephosphorylation of PIP3 is first order with rate constant $k_{\\mathrm{PTEN}}$, and that the system reaches a quasi-steady state with $\\mathrm{d}[ \\mathrm{PIP3} ]/\\mathrm{d}t = 0$. Protein kinase B (AKT) activation is taken to be proportional to its membrane recruitment via pleckstrin homology domain binding to PIP3, modeled as equilibrium ligand binding with dissociation constant $K_{d}$, and total AKT concentration $[\\mathrm{AKT}]_{\\mathrm{tot}}$ is the same across conditions.\n\nCells harboring the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) H1047R mutation exhibit an increased catalytic capacity of PI3K relative to wild-type. Let the parameters be:\n- $[ \\mathrm{PIP2} ] = 5~\\mu\\mathrm{M}$,\n- $K_{m} = 2~\\mu\\mathrm{M}$,\n- $k_{\\mathrm{PTEN}} = 0.1~\\mathrm{min}^{-1}$,\n- wild-type $V_{\\max}^{\\mathrm{WT}} = 0.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}$,\n- H1047R mutant $V_{\\max}^{\\mathrm{Mut}} = 1.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}$,\n- AKT–PIP3 dissociation constant $K_{d} = 1~\\mu\\mathrm{M}$,\n- $[\\mathrm{AKT}]_{\\mathrm{tot}} = 1~\\mu\\mathrm{M}$.\n\nUsing only the stated biophysical bases and the steady-state condition, compute the fold-change in activated AKT concentration (mutant to wild-type), expressed as a dimensionless decimal. Round your final answer to four significant figures. Do not report intermediate values; only report the requested fold-change.",
            "solution": "The rate of change of the concentration of PIP3, denoted as $[\\mathrm{PIP3}]$, is determined by its production by PI3K and its removal by PTEN. The rate equation is:\n$$\n\\frac{\\mathrm{d}[\\mathrm{PIP3}]}{\\mathrm{d}t} = (\\text{rate of production}) - (\\text{rate of removal})\n$$\nThe production of PIP3 by PI3K from its substrate PIP2 follows Michaelis-Menten kinetics:\n$$\nv_{\\mathrm{prod}} = \\frac{V_{\\max} [\\mathrm{PIP2}]}{K_m + [\\mathrm{PIP2}]}\n$$\nThe removal of PIP3 by PTEN is a first-order process:\n$$\nv_{\\mathrm{rem}} = k_{\\mathrm{PTEN}} [\\mathrm{PIP3}]\n$$\nThus, the full rate equation for $[\\mathrm{PIP3}]$ is:\n$$\n\\frac{\\mathrm{d}[\\mathrm{PIP3}]}{\\mathrm{d}t} = \\frac{V_{\\max} [\\mathrm{PIP2}]}{K_m + [\\mathrm{PIP2}]} - k_{\\mathrm{PTEN}} [\\mathrm{PIP3}]\n$$\nThe problem states that the system is at a quasi-steady state, which implies $\\frac{\\mathrm{d}[\\mathrm{PIP3}]}{\\mathrm{d}t} = 0$. At steady state, the production and removal rates are equal:\n$$\n\\frac{V_{\\max} [\\mathrm{PIP2}]}{K_m + [\\mathrm{PIP2}]} = k_{\\mathrm{PTEN}} [\\mathrm{PIP3}]_{\\mathrm{ss}}\n$$\nWe can solve for the steady-state concentration of PIP3, $[\\mathrm{PIP3}]_{\\mathrm{ss}}$:\n$$\n[\\mathrm{PIP3}]_{\\mathrm{ss}} = \\frac{1}{k_{\\mathrm{PTEN}}} \\left( \\frac{V_{\\max} [\\mathrm{PIP2}]}{K_m + [\\mathrm{PIP2}]} \\right)\n$$\nWe compute $[\\mathrm{PIP3}]_{\\mathrm{ss}}$ for both the wild-type (WT) and mutant (Mut) conditions.\n\nFor the wild-type condition:\n$V_{\\max}^{\\mathrm{WT}} = 0.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}$, $[\\mathrm{PIP2}] = 5~\\mu\\mathrm{M}$, $K_m = 2~\\mu\\mathrm{M}$, and $k_{\\mathrm{PTEN}} = 0.1~\\mathrm{min}^{-1}$.\n$$\n[\\mathrm{PIP3}]_{\\mathrm{ss}}^{\\mathrm{WT}} = \\frac{1}{0.1~\\mathrm{min}^{-1}} \\left( \\frac{(0.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}) (5~\\mu\\mathrm{M})}{2~\\mu\\mathrm{M} + 5~\\mu\\mathrm{M}} \\right) = 10 \\left( \\frac{2.5}{7} \\right) \\mu\\mathrm{M} = \\frac{25}{7}~\\mu\\mathrm{M}\n$$\nFor the mutant condition:\n$V_{\\max}^{\\mathrm{Mut}} = 1.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}$, with all other parameters remaining the same.\n$$\n[\\mathrm{PIP3}]_{\\mathrm{ss}}^{\\mathrm{Mut}} = \\frac{1}{0.1~\\mathrm{min}^{-1}} \\left( \\frac{(1.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}) (5~\\mu\\mathrm{M})}{2~\\mu\\mathrm{M} + 5~\\mu\\mathrm{M}} \\right) = 10 \\left( \\frac{7.5}{7} \\right) \\mu\\mathrm{M} = \\frac{75}{7}~\\mu\\mathrm{M}\n$$\nNext, we determine the concentration of activated AKT, $[\\mathrm{AKT}]_{\\mathrm{act}}$. This is modeled as the concentration of AKT bound to PIP3 at equilibrium. The binding reaction is $\\mathrm{AKT} + \\mathrm{PIP3} \\rightleftharpoons \\mathrm{AKT-PIP3}$. Using the law of mass action for the dissociation constant $K_d$:\n$$\nK_d = \\frac{[\\mathrm{AKT}]_{\\mathrm{free}} [\\mathrm{PIP3}]_{\\mathrm{ss}}}{[\\mathrm{AKT}]_{\\mathrm{act}}}\n$$\nWith the conservation of total AKT, $[\\mathrm{AKT}]_{\\mathrm{tot}} = [\\mathrm{AKT}]_{\\mathrm{free}} + [\\mathrm{AKT}]_{\\mathrm{act}}$, we can substitute $[\\mathrm{AKT}]_{\\mathrm{free}} = [\\mathrm{AKT}]_{\\mathrm{tot}} - [\\mathrm{AKT}]_{\\mathrm{act}}$ into the equation:\n$$\nK_d = \\frac{([\\mathrm{AKT}]_{\\mathrm{tot}} - [\\mathrm{AKT}]_{\\mathrm{act}}) [\\mathrm{PIP3}]_{\\mathrm{ss}}}{[\\mathrm{AKT}]_{\\mathrm{act}}}\n$$\nSolving for $[\\mathrm{AKT}]_{\\mathrm{act}}$ yields the Hill-Langmuir equation:\n$$\n[\\mathrm{AKT}]_{\\mathrm{act}} = \\frac{[\\mathrm{AKT}]_{\\mathrm{tot}} [\\mathrm{PIP3}]_{\\mathrm{ss}}}{K_d + [\\mathrm{PIP3}]_{\\mathrm{ss}}}\n$$\nWe now calculate $[\\mathrm{AKT}]_{\\mathrm{act}}$ for both WT and Mut conditions using $[\\mathrm{AKT}]_{\\mathrm{tot}} = 1~\\mu\\mathrm{M}$ and $K_d = 1~\\mu\\mathrm{M}$.\n\nFor the wild-type condition:\n$$\n[\\mathrm{AKT}]_{\\mathrm{act}}^{\\mathrm{WT}} = \\frac{(1~\\mu\\mathrm{M}) \\left(\\frac{25}{7}~\\mu\\mathrm{M}\\right)}{1~\\mu\\mathrm{M} + \\frac{25}{7}~\\mu\\mathrm{M}} = \\frac{\\frac{25}{7}}{\\frac{7+25}{7}}~\\mu\\mathrm{M} = \\frac{25}{32}~\\mu\\mathrm{M}\n$$\nFor the mutant condition:\n$$\n[\\mathrm{AKT}]_{\\mathrm{act}}^{\\mathrm{Mut}} = \\frac{(1~\\mu\\mathrm{M}) \\left(\\frac{75}{7}~\\mu\\mathrm{M}\\right)}{1~\\mu\\mathrm{M} + \\frac{75}{7}~\\mu\\mathrm{M}} = \\frac{\\frac{75}{7}}{\\frac{7+75}{7}}~\\mu\\mathrm{M} = \\frac{75}{82}~\\mu\\mathrm{M}\n$$\nFinally, we compute the fold-change, $F$, which is the ratio of the mutant activated AKT concentration to the wild-type activated AKT concentration.\n$$\nF = \\frac{[\\mathrm{AKT}]_{\\mathrm{act}}^{\\mathrm{Mut}}}{[\\mathrm{AKT}]_{\\mathrm{act}}^{\\mathrm{WT}}} = \\frac{\\frac{75}{82}~\\mu\\mathrm{M}}{\\frac{25}{32}~\\mu\\mathrm{M}} = \\frac{75}{82} \\times \\frac{32}{25} = \\frac{3 \\times 25}{82} \\times \\frac{32}{25} = \\frac{3 \\times 32}{82} = \\frac{96}{82} = \\frac{48}{41}\n$$\nTo obtain the final decimal answer, we perform the division and round to four significant figures.\n$$\nF = \\frac{48}{41} \\approx 1.1707317...\n$$\nRounding to four significant figures gives $1.171$.",
            "answer": "$$\n\\boxed{1.171}\n$$"
        },
        {
            "introduction": "Cellular signaling networks are rarely linear; they are rich with feedback loops that produce complex and often counter-intuitive behaviors. This exercise explores the famous negative feedback loop where mTORC1, a downstream effector, inhibits the activity of IRS1, an upstream activator. Understanding this motif is crucial for predicting the effects of targeted therapies, as inhibiting one component can have unexpected consequences on others. This practice  challenges you to model this circuit to explain the paradoxical \"rebound\" activation of AKT following treatment with the mTORC1 inhibitor rapamycin, a classic example of systems-level effects in pharmacology.",
            "id": "4358767",
            "problem": "A signaling network module linking insulin receptor substrate 1 (IRS1), phosphoinositide 3-kinase (PI3K), and mechanistic target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2) is modeled under the following assumptions grounded in standard mass-action and Hill-type saturation kinetics. Negative feedback from mTORC1 to IRS1 via ribosomal protein S6 kinase (S6K) reduces effective IRS1 activity. Acute rapamycin treatment inhibits mechanistic target of rapamycin complex 1 (mTORC1) but does not directly inhibit mechanistic target of rapamycin complex 2 (mTORC2). Increased PI3K output increases phosphatidylinositol-3,4,5-trisphosphate (PIP3), enhancing membrane recruitment of AKT and thereby increasing the rate of AKT Serine 473 phosphorylation by mTORC2. Assume quasi-steady state on the time scale of interest and that catalytic capacity of mTORC2 remains constant during the perturbation.\n\nUse the following constitutive relationships and parameters:\n\n- Effective IRS1 activity is reduced by mTORC1-dependent feedback according to the saturating inhibition form $I = \\dfrac{I_{0}}{1 + \\alpha M}$, where $I_{0}$ is the ligand-driven IRS1 input in the absence of feedback, $\\alpha$ is the dimensionless feedback strength, and $M$ is the dimensionless mTORC1 output.\n- Rapamycin reduces mTORC1 output by a fractional efficacy $e$, so that $M_{\\text{post}} = (1 - e) M_{\\text{pre}}$.\n- PI3K output follows a Hill activation by IRS1: $P = P_{\\max} \\dfrac{I^{n}}{K^{n} + I^{n}}$, where $P_{\\max}$ is the maximum PI3K output, $K$ is the half-activation constant, and $n$ is the Hill coefficient.\n- AKT Serine 473 phosphorylation level $S$ is proportional to PI3K output due to substrate availability to mechanistic target of rapamycin complex 2 (mTORC2), i.e., $S = c\\,P$, where $c$ is a constant that absorbs mTORC2 catalytic capacity and AKT abundance.\n- Define the rebound fold-change as $F = \\dfrac{S_{\\text{post}}}{S_{\\text{pre}}}$.\n\nParameters (all dimensionless or in consistent arbitrary units): $I_{0} = 1.0$, $\\alpha = 1.5$, $M_{\\text{pre}} = 2.0$, $e = 0.7$, $P_{\\max} = 1.0$, $K = 0.3$, $n = 2$.\n\nCompute the rebound fold-change $F$ for AKT Serine 473 phosphorylation after rapamycin treatment arising solely from relief of mTORC1-to-IRS1 feedback under this model. Express the result as a dimensionless number and round your answer to three significant figures.",
            "solution": "The objective is to compute the rebound fold-change $F$ for AKT Serine 473 phosphorylation, defined as $F = \\dfrac{S_{\\text{post}}}{S_{\\text{pre}}}$. The subscripts \"pre\" and \"post\" refer to the states before and after rapamycin treatment, respectively.\n\nGiven the relationship $S = c\\,P$, where $c$ is a constant, the fold-change $F$ can be expressed in terms of PI3K output $P$:\n$$F = \\frac{S_{\\text{post}}}{S_{\\text{pre}}} = \\frac{c\\,P_{\\text{post}}}{c\\,P_{\\text{pre}}} = \\frac{P_{\\text{post}}}{P_{\\text{pre}}}$$\nThe constant of proportionality $c$ cancels out.\n\nNext, we substitute the expression for PI3K output, $P = P_{\\max} \\dfrac{I^{n}}{K^{n} + I^{n}}$, into the equation for $F$:\n$$F = \\frac{P_{\\max} \\dfrac{I_{\\text{post}}^{n}}{K^{n} + I_{\\text{post}}^{n}}}{P_{\\max} \\dfrac{I_{\\text{pre}}^{n}}{K^{n} + I_{\\text{pre}}^{n}}}$$\nThe maximum PI3K output, $P_{\\max}$, also cancels, yielding an expression for $F$ that depends only on the effective IRS1 activities ($I_{\\text{pre}}, I_{\\text{post}}$) and the Hill parameters ($K, n$):\n$$F = \\frac{I_{\\text{post}}^{n}}{I_{\\text{pre}}^{n}} \\cdot \\frac{K^{n} + I_{\\text{pre}}^{n}}{K^{n} + I_{\\text{post}}^{n}}$$\n\nThe solution requires a step-by-step calculation of the required quantities.\n\n1.  **Calculate post-treatment mTORC1 output ($M_{\\text{post}}$)**:\n    Given $M_{\\text{pre}} = 2.0$ and rapamycin efficacy $e = 0.7$, the post-treatment mTORC1 output is:\n    $$M_{\\text{post}} = (1 - e) M_{\\text{pre}} = (1 - 0.7) \\times 2.0 = 0.3 \\times 2.0 = 0.6$$\n\n2.  **Calculate pre-treatment effective IRS1 activity ($I_{\\text{pre}}$)**:\n    Using the given parameters $I_{0} = 1.0$, $\\alpha = 1.5$, and $M_{\\text{pre}} = 2.0$:\n    $$I_{\\text{pre}} = \\frac{I_{0}}{1 + \\alpha M_{\\text{pre}}} = \\frac{1.0}{1 + (1.5)(2.0)} = \\frac{1.0}{1 + 3.0} = \\frac{1.0}{4.0} = 0.25$$\n\n3.  **Calculate post-treatment effective IRS1 activity ($I_{\\text{post}}$)**:\n    Using $I_{0} = 1.0$, $\\alpha = 1.5$, and the calculated $M_{\\text{post}} = 0.6$:\n    $$I_{\\text{post}} = \\frac{I_{0}}{1 + \\alpha M_{\\text{post}}} = \\frac{1.0}{1 + (1.5)(0.6)} = \\frac{1.0}{1 + 0.9} = \\frac{1.0}{1.9}$$\n\n4.  **Calculate the rebound fold-change ($F$)**:\n    Now, we substitute the values of $I_{\\text{pre}}$, $I_{\\text{post}}$, and the parameters $K = 0.3$ and $n = 2$ into the expression for $F$.\n    $$F = \\left(\\frac{I_{\\text{post}}}{I_{\\text{pre}}}\\right)^{n} \\frac{K^{n} + I_{\\text{pre}}^{n}}{K^{n} + I_{\\text{post}}^{n}}$$\n    We compute the necessary terms:\n    -   $I_{\\text{pre}}^{n} = I_{\\text{pre}}^{2} = (0.25)^{2} = 0.0625$\n    -   $I_{\\text{post}}^{n} = I_{\\text{post}}^{2} = \\left(\\frac{1.0}{1.9}\\right)^{2} = \\frac{1.0}{3.61}$\n    -   $K^{n} = K^{2} = (0.3)^{2} = 0.09$\n\n    Substitute these values into the expression for $F$:\n    $$F = \\frac{\\frac{1.0}{3.61}}{0.0625} \\cdot \\frac{0.09 + 0.0625}{0.09 + \\frac{1.0}{3.61}}$$\n    First, evaluate the numerator and denominator of the second fraction:\n    -   Numerator: $0.09 + 0.0625 = 0.1525$\n    -   Denominator: $0.09 + \\frac{1.0}{3.61} = \\frac{0.09 \\times 3.61 + 1.0}{3.61} = \\frac{0.3249 + 1.0}{3.61} = \\frac{1.3249}{3.61}$\n\n    Now, substitute these back into the expression for $F$:\n    $$F = \\left(\\frac{1.0}{3.61 \\times 0.0625}\\right) \\cdot \\frac{0.1525}{\\frac{1.3249}{3.61}} = \\left(\\frac{1.0}{0.225625}\\right) \\cdot \\left(\\frac{0.1525 \\times 3.61}{1.3249}\\right)$$\n    The calculation simplifies to:\n    $$F = \\frac{0.1525}{0.0625} \\cdot \\frac{1}{\\frac{1.3249}{3.61}} \\cdot \\frac{1}{3.61} = \\frac{0.1525}{0.0625} \\cdot \\frac{1}{1.3249} = \\frac{0.1525}{0.0625 \\times 1.3249} = \\frac{0.1525}{0.08280625}$$\n    $$F \\approx 1.84164$$\n\nThe problem requires the result to be rounded to three significant figures.\n$$F \\approx 1.84$$\n\nThis result quantifies the paradoxical rebound in AKT Serine 473 phosphorylation that occurs due to the relief of negative feedback when mTORC1 is acutely inhibited. The fold-change greater than $1$ indicates an increase in the signal.",
            "answer": "$$\\boxed{1.84}$$"
        },
        {
            "introduction": "The ultimate purpose of many signaling pathways is to control cellular decisions by regulating gene expression. However, the information is often encoded in the dynamics of the signal, such as its duration or frequency. This practice explores how the transcriptional machinery decodes a dynamic input from the MAPK pathway into a specific gene expression output. By modeling ERK activity as a pulse and describing mRNA accumulation with a first-order ordinary differential equation, you can analyze how signal duration is translated into a biological response. This exercise  develops your ability to connect transient signaling events to their functional consequences, a key concept in cellular information processing.",
            "id": "4358781",
            "problem": "Consider the coupling of the Mitogen-Activated Protein Kinase (MAPK) module, specifically Extracellular signal-Regulated Kinase (ERK), to transcriptional control, within a cell that also engages the Phosphoinositide 3-kinase (PI3K)-AKT-mechanistic Target Of Rapamycin (mTOR) axis. Assume that translational regulation by the PI3K-AKT-mTOR pathway is held constant over the time window of interest, so that the dominant time dependence of gene expression output arises from ERK-dependent transcription. The nuclear activity of ERK is modeled as a square pulse of amplitude $E_{0}$ and duration $T$, so that $E(t) = E_{0}$ for $0 \\le t \\le T$ and $E(t) = 0$ otherwise. The promoter occupancy mapping from ERK nuclear activity to a transcription initiation rate is modeled by a Hill function based on cooperative binding, a well-tested approximation for multi-site regulatory interactions. Let the instantaneous transcription rate be $r(t) = r_{\\max}\\,\\frac{E(t)^{n}}{K^{n} + E(t)^{n}}$, where $r_{\\max}$ is the maximal transcription rate, $K$ is the half-activation constant, and $n$ is the Hill coefficient. The messenger ribonucleic acid (mRNA) concentration $m(t)$ obeys first-order turnover $\\frac{dm}{dt} = r(t) - \\gamma\\,m(t)$ with initial condition $m(0) = 0$, where $\\gamma$ is the mRNA degradation rate constant. Derive, from these base assumptions, the closed-form expression for the mRNA concentration $m(T)$ at the end of the ERK pulse. Then, for two distinct pulse durations $T_{1}$ and $T_{2}$ applied with the same $E_{0}$, $n$, $K$, $r_{\\max}$, and $\\gamma$, compute the fold-change in transcriptional output defined as $\\Phi = \\frac{m(T_{2})}{m(T_{1})}$. Express your final answer as a single closed-form analytic expression in terms of $T_{1}$, $T_{2}$, and $\\gamma$. Do not include units. No numerical rounding is required.",
            "solution": "The problem asks for two derivations. First, an expression for the messenger ribonucleic acid (mRNA) concentration, $m(t)$, at the end of a square pulse of Extracellular signal-Regulated Kinase (ERK) activity of duration $T$. Second, the fold-change in this final mRNA concentration for two different pulse durations, $T_1$ and $T_2$.\n\nThe nuclear ERK activity, $E(t)$, is modeled as a square pulse:\n$$\nE(t) =\n\\begin{cases}\nE_{0} & \\text{for } 0 \\le t \\le T \\\\\n0 & \\text{otherwise}\n\\end{cases}\n$$\nThe instantaneous transcription rate, $r(t)$, is a Hill function of $E(t)$:\n$$r(t) = r_{\\max}\\,\\frac{E(t)^{n}}{K^{n} + E(t)^{n}}$$\nDuring the stimulus pulse, for the time interval $0 \\le t \\le T$, the ERK activity is constant at $E(t) = E_0$. Consequently, the transcription rate is also constant during this interval. Let us define this constant rate as $r_0$:\n$$r_{0} = r_{\\max}\\,\\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}}$$\nThe dynamics of the mRNA concentration, $m(t)$, are described by the first-order linear ordinary differential equation (ODE):\n$$\\frac{dm}{dt} = r(t) - \\gamma\\,m(t)$$\nwith the initial condition $m(0) = 0$.\n\nFor the interval $0 \\le t \\le T$, the ODE simplifies to:\n$$\\frac{dm}{dt} = r_0 - \\gamma\\,m(t)$$\nThis can be rewritten in standard form for a first-order linear ODE:\n$$\\frac{dm}{dt} + \\gamma\\,m(t) = r_0$$\nTo solve this equation, we use an integrating factor, $I(t)$, defined as:\n$$I(t) = \\exp\\left(\\int \\gamma \\, dt\\right) = \\exp(\\gamma t)$$\nMultiplying the ODE by the integrating factor $I(t)$ gives:\n$$\\exp(\\gamma t)\\frac{dm}{dt} + \\gamma\\exp(\\gamma t)m(t) = r_0\\exp(\\gamma t)$$\nThe left-hand side is the result of the product rule for differentiation applied to $m(t)\\exp(\\gamma t)$:\n$$\\frac{d}{dt}\\left(m(t)\\exp(\\gamma t)\\right) = r_0\\exp(\\gamma t)$$\nIntegrating both sides with respect to time $t$:\n$$\\int \\frac{d}{dt}\\left(m(t)\\exp(\\gamma t)\\right) dt = \\int r_0\\exp(\\gamma t) dt$$\n$$m(t)\\exp(\\gamma t) = \\frac{r_0}{\\gamma}\\exp(\\gamma t) + C$$\nwhere $C$ is the constant of integration. We determine $C$ using the initial condition $m(0) = 0$:\n$$m(0)\\exp(\\gamma \\cdot 0) = \\frac{r_0}{\\gamma}\\exp(\\gamma \\cdot 0) + C$$\n$$0 \\cdot 1 = \\frac{r_0}{\\gamma} \\cdot 1 + C$$\n$$C = -\\frac{r_0}{\\gamma}$$\nSubstituting the value of $C$ back into the general solution:\n$$m(t)\\exp(\\gamma t) = \\frac{r_0}{\\gamma}\\exp(\\gamma t) - \\frac{r_0}{\\gamma}$$\nTo obtain the final expression for $m(t)$, we isolate $m(t)$ by multiplying by $\\exp(-\\gamma t)$:\n$$m(t) = \\frac{r_0}{\\gamma}\\left(1 - \\exp(-\\gamma t)\\right)$$\nThis is the closed-form expression for the mRNA concentration for $0 \\le t \\le T$.\n\nThe first part of the problem asks for the mRNA concentration at the end of the pulse, $m(T)$. We find this by substituting $t=T$ into our solution:\n$$m(T) = \\frac{r_0}{\\gamma}\\left(1 - \\exp(-\\gamma T)\\right)$$\nSubstituting the expression for $r_0$:\n$$m(T) = \\left( \\frac{r_{\\max}}{\\gamma} \\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}} \\right) \\left(1 - \\exp(-\\gamma T)\\right)$$\n\nThe second part of the problem asks for the fold-change $\\Phi = \\frac{m(T_{2})}{m(T_{1})}$ for two different pulse durations $T_1$ and $T_2$, with all other parameters ($E_0$, $n$, $K$, $r_{\\max}$, $\\gamma$) remaining constant.\nWe write the expressions for $m(T_1)$ and $m(T_2)$:\n$$m(T_1) = \\left( \\frac{r_{\\max}}{\\gamma} \\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}} \\right) \\left(1 - \\exp(-\\gamma T_1)\\right)$$\n$$m(T_2) = \\left( \\frac{r_{\\max}}{\\gamma} \\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}} \\right) \\left(1 - \\exp(-\\gamma T_2)\\right)$$\nNow, we compute the ratio $\\Phi$:\n$$\\Phi = \\frac{m(T_2)}{m(T_1)} = \\frac{\\left( \\frac{r_{\\max}}{\\gamma} \\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}} \\right) \\left(1 - \\exp(-\\gamma T_2)\\right)}{\\left( \\frac{r_{\\max}}{\\gamma} \\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}} \\right) \\left(1 - \\exp(-\\gamma T_1)\\right)}$$\nThe pre-factor term, $\\left( \\frac{r_{\\max}}{\\gamma} \\frac{E_{0}^{n}}{K^{n} + E_{0}^{n}} \\right)$, which contains all parameters except the pulse duration, is common to both the numerator and the denominator and thus cancels out. This leaves a simplified expression for the fold-change that depends only on the pulse durations $T_1$, $T_2$, and the mRNA degradation rate $\\gamma$:\n$$\\Phi = \\frac{1 - \\exp(-\\gamma T_2)}{1 - \\exp(-\\gamma T_1)}$$\nThis is the required final expression.",
            "answer": "$$\\boxed{\\frac{1 - \\exp(-\\gamma T_{2})}{1 - \\exp(-\\gamma T_{1})}}$$"
        }
    ]
}